No reviews yet.
A formidable challenge of globalization, is governments' inability to effectively monitor and regulate these emerging technologies - and the increasing commitment and wherewithal of non-state actors to use these advances for hostile purposes.
This report uses a case study industry's growing interest in dangerous pathogens and toxins as therapeutic pharmaceuticals. It illustrates the full life-cycle of threats and opportunities from research to distribution to injection into patient of products derived from select agents.